Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: The Idaho State Journal reports that last year there were nearly 6,600 STD cases, including HIV, up from fewer than 6,300 in 2016. Cases are also up nationally, with Centers for Disease Control and Prevention announcing last week that nearly 2.3 million cases of chlamydia, gonorrhea and syphilis were diagnosed in the United States in 2017. Kimberly Matulonis-Edgar of the Idaho Department of Health and Welfare says experts in the state and across the country are struggling to understand what’s driving the increase. The most prevalent STDs reported nationally and in Idaho are gonorrhea and chlamydia. State health officials say that the rate of reported gonorrhea cases in Southeast Idaho fell about 14 percent from a year ago, but jumped more than 200 percent in south-central Idaho. ___ Information from: Idaho State Journal, http://www.journalnet.com Claim: Health experts alarmed by jump in STDs in Idaho.

A: A jump in reports of sexually transmitted diseases in Idaho has health experts worried.
****
Q: Paragraph: Yet nothing prepared residents of its oldest town, Graaff-Reinet, for their worst drought in more than a century. As the dry spell entered its fourth year, tap water turned brown and smelled like rotting fish. When the water behind the Nqweba Dam dried up, depositing tens of thousands of dead fish onto cracked earth, queues began forming at municipal bore holes and farm animals died in their hundreds. The bleak choices facing millions of people in drought-stricken southern Africa - whether to flush toilets or not, or to keep animals alive or let them die - could soon be faced by other places on a warming planet with shrinking water supplies. “This area is dry but our taps have never been completely empty. Never,” said Bukelwa Booysen, who has had to send staff in search of borehole water for her school for disabled children, and send the kids home when they can’t find any. An abnormally hot summer with rainfall 75% below average, according to the U.S. National Oceanic and Atmospheric Administration, has struck the whole region. The United Nations says 45 million people in southern Africa face hunger. Bushes and trees clinging to the Karoo’s rocky ravines are withered and grey - even hardy acacia thorns are dying. Signs mark rivers that are now dry beds. At one farm, Gerrie Snyman, 65, was feeding grain to sheep and goats that couldn’t find pasture. More than a third of his couple-thousand goats and sheep had either died or been sold this year. His 80 cows were now 15. He loaded a calf that was starving - its mother had stopped producing milk - onto his truck to take home and shoot. A friend had shot himself dead after his animals died of thirst. “We are grateful to the Almighty for our borehole water,” he said. “We don’t know what we’ll do when it runs out.”   When Cape Town’s reservoir nearly ran dry 18 months ago, it made international headlines and authorities rationed water. Yet Karoo is long past water rationing. For Valentia Esho, 45, an unemployed mother of seven in the township of Umazisakhe, it means letting her toilet fill up  instead of flushing, never washing clothes and only washing plates that stink. Water is just for drinking. “The house is really smelling,” she said, inside her one-room brick-and-tin home. “Everyone is paining from stomach aches and diarrhoea.”   In another township, Asherville, where wind kicked up dust devils, school headmaster Basil Vaaltyn was overseeing water distribution from a truck. He’d done everything to cut down on his usage: “I’m down to a minute showering instead of two.” His wife saves dirty dishwater to fill the cistern. A spokesman for the municipality said it was drilling boreholes, installing pipelines and building an 18-million-litre reservoir, adding: “Usage of water is still very high. The community is requested to use water sparingly.”  With municipal authorities overwhelmed, South African charity Gift of the Givers is trucking water to townships and drilling boreholes. Gideon Groenewald, a geohydrologist for the charity, uses science and spirituality to look for groundwater. When he was growing up on a farm, he used to dowse with wet twigs. Nowadays he prefers magnetic detectors. “I open Google maps and look for the lines of trees. I ask God in prayer which lines hold water, then I go down to that GPS location,” he said while a forked stick turned in his hand over an arid patch of shrubs. “You see the stick moving where the magnetic field is? There’s water here,” he continued. “It’s pure science.”  The charity has drilled 1,800 boreholes in the past three years, Groenewald said, only a third of them dry. But Louise Stafford, water director for the Nature Conservancy in South Africa, urged caution with boreholes, because groundwater is a finite resource. Water-intensive agriculture like citrus farms can make droughts worse, she said, and leaky pipes are losing a billion litres a year - problems Water Minister Lindiwe Sisulu pledged to tackle in a new water masterplan she delivered on Thursday. One Sunday, as clouds formed over Graaff-Reinet, its Assembly Church prayed. The clouds spat but didn’t pour. “We pray for God to open heaven and send rain,” Pastor Dolan Cochrane said. The congregation bowed. “Lord,” Cochrane continued. “We know that, in your time, you will come to our rescue.” Claim: South Africa's Karoo drills and prays as taps run dry.

A: South Africa’s Karoo region has always been parched - it means land of thirst in the language of its earliest inhabitants, the Khoisan hunter gatherers.
****
Q: Paragraph: According to the story, brand-name aromatase inhibitors cost between $340 and $420 a month, but the story also points out that lower-costing, generic versions are available in the U.S. It would have been useful had the story also provided cost information for the other preventive drug options, tamoxifen and raloxifene. A particular strength of this story is its presentation of data. Dr. Winer, an independent source included in the story, translates a 65% risk reduction to mean that exemestane may reduce a woman’s risk of developing breast cancer from 3% to 1%. Not only does the story provide absolute risk, but it also presents the number needed to treat. According to the study authors, 26 women would need to take exemestane for five years to prevent a single case of breast cancer. It should be noted, however, that few women in the study completed five years of therapy. Since this is being used as a preventive measure in healthy women, side effects are very important and data should have been provided. The story indicates that “slightly” more women taking exemastane experienced hot flashes, fatigue, sweating, insomnia, and joint pain, compared to those taking placebo pills. It would have been helpful to note, for example, that 40% in the exemestane group experienced a hot flash versus 32% in the placebo group. Citing older research, the story indicates that that joint pain, muscle aches, problems having sex, and vaginal dryness may be more evident with a longer duration of use. The story makes it clear that the study was a large-scale, placebo-controlled, randomized trial, which enrolled over 4500 women in North America and Europe. The women included had at least one risk factor for breast cancer. It also notes that given the significant risk reduction associated with exemestane, the study was stopped after 3 years to give women in the control arm the option of taking exemestane to prevent possible breast cancers. More information regarding participants’ characteristics, including age and race would have been helpful. This story did not engage in disease-mongering. In addition to including experts not affiliated with the exemestane study, the story also notes that the it was funded by the Canadian Cancer Society, the Avon Foundation, and Pfizer. In addition, the writer points out that the study lead and a few other authors have received speaking fees from Pfizer and other pharmaceutical companies that make cancer drugs. This story compares the benefits and harms of exemestane with tamoxifen; however, a mention of how these compare with raloxifene, would have been useful. The availability of aromatase inhibitors is not in question. It’s clear from the story that aromatase inhibitors are currently used to prevent breast cancer recurrences. It’s also clear that this is the first study evaluating its utility for preventing the first instance of breast cancer in healthy women with a higher risk of developing the disease. The story does not appear to be based on the press release. Claim: Hormone-blocking drug reduces breast cancer risk

A:
This story reports on results from a double-blind, placebo-controlled, randomized trial, which found that the aromatase inhibitor, exemestane, is an effective option for preventing breast cancer in higher risk, postmenopausal women. The story does a nice job of discussing the study, presenting the outcomes, and framing it as a decision to be made after weighing the potential benefits and harms. However, we would have liked to have seen a broader discussion on whether healthy women would really want to take a medication with potentially serious side effects and only a modest benefit. There are significant side effects associated with tamoxifen and raloxifene and many women feel these potential harms outweigh the potential benefit of reducing their risk of developing cancer. Aromatase inhibitors have fewer side effects and may be a more attractive option for postmenopausal women who have an increased risk of breast cancer; however, studies have shown that a very small percentage of women in this higer risk group have any desire to take tamoxifen. It’s unclear whether aromatase inhibitors provide enough benefit to change womens’ preferences. In addition, about half of patients using aromatase inhibitors to prevent a recurrence of breast cancer have stopped taking the drug after just 2 years, so these drugs are not without problems. One could argue that nonadherence would be even greater in healthy women taking it to prevent a first breast cancer.
****